Efficacy and Safety of Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist, in People with Type 2 Diabetes and Inadequate Glycaemic Control with Diet and Exercise (TRANSCEND-T2D-1): A Double-Blind, Randomised, Phase 3 Trial
Personalized evaluation outperforms generic tirzepatide microdosing plans
21 Radioligand-binding studies have shown high densities of GLP-1 receptors in the lateral septum, the subfornical organ, the thalamus, the hypothalamus, the interpenduncular nucleus, the posterodorsal tegmental nucleus, the area postrema (AP), the inferior olive and the nucleus tractus solitarius (NTS)
It works by slowing digestion and increasing feelings of fullness, which reduces overall calorie intake